Abbott Laboratories stock weighs Amulet 360 heart-device data

Published on 11/10/2026 at 13:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Abbott Laboratories stock is weighing one-year data for the investigational Amulet 360 heart device. U.S. approval remains a key next step.

Heart Device Data Raise Stakes

Abbott reported one-year VERITAS results for the investigational Amulet 360 device on November 2.
The device remains investigational in the United States, while Abbott said it received CE Mark approval in August 2026.
Investors will focus on regulatory progress and the conversion of clinical performance into commercial use.

Abbott Laboratories, US0028241000, Illustration mit AI erstellt.

Abbott Laboratories reported one-year results for its investigational Amulet 360 left atrial appendage occluder on November 2, adding a fresh clinical milestone to the company's cardiology pipeline. The findings were presented at the Transcatheter Cardiovascular Therapeutics conference on November 1 and published simultaneously in JACC: Cardiovascular Interventions. PR Newswire carried Abbott's announcement.

Clinical Results Support Device Case

The VERITAS pivotal study found complete closure of the left atrial appendage, defined as a zero-millimeter leak on transesophageal echocardiography, in 96.3% of evaluated patients. More than 98% remained free from ischemic stroke or systemic embolism through one year, while more than 99% avoided pericardial effusion requiring intervention.

Abbott also said more than 98% of patients were free from cardiovascular-related mortality and that major bleeding events were absent in 93.4% of patients during the first year of follow-up. The study enrolled more than 450 patients, including roll-in patients, at more than 30 hospitals in the United States, Canada and Europe.

U.S. Regulatory Step Still Ahead

Amulet 360 is designed for people with non-valvular atrial fibrillation who may need an alternative to long-term blood-thinning medication. Abbott said the device uses a softer, more conformable implant body and an outer disc that provides a second sealing layer.

The device is approved for investigational use only in the United States. Abbott said it received CE Mark approval in August 2026. That regulatory distinction keeps future U.S. authorization, reimbursement and physician adoption as central milestones for the commercial investment case.

For Abbott, the results strengthen the medical-device narrative but do not by themselves establish future revenue. The next test is whether clinical performance can translate into regulatory clearance, procedure volumes and durable adoption. The company also faces the execution demands that come with manufacturing, training and post-market oversight for complex cardiac products.

Quote Adds A Current Market Signal

Abbott Laboratories stock traded at 98.62 euros on Lang & Schwarz at 13:01 CET on Tuesday, November 10, 2026. The quote provides a current trading reference as investors assess whether the cardiology pipeline can support longer-term growth alongside Abbott's established diagnostics, nutrition and pharmaceutical businesses.